メチレンブルー静注50mg「第一三共」添付文書 [Methylene Blue Intravenous Injection 50 mg ‘Daiichi Sankyo’ – Japanese package insert] (2024)

Government Record · Daiichi Sankyo Co., Ltd. (manufacturer); label distributed via JAPIC PINS (Japan Pharmaceutical Information Center) · October 2024

Daiichi Sankyo Co. et al., 2024-10: Japanese package insert for Methylene Blue Intravenous Injection 50 mg (Daiichi Sankyo), approved under number 22600AMX01391 and marketed since March 2015, indicated for toxic methemoglobinemia at 1-2 mg/kg intravenously with a maximum cumulative dose of 7 mg/kg.

4. 効能又は効果 中毒性メトヘモグロビン血症

1

Daiichi Sankyo Co. et al., 2024-10: Japanese package insert for Methylene Blue Intravenous Injection 50 mg (Daiichi Sankyo), approved under number 22600AMX01391 and marketed since March 2015, indicated for toxic methemoglobinemia at 1-2 mg/kg intravenously with a maximum cumulative dose of 7 mg/kg. C3 Japan – approval/label record. Product: メチレンブルー静注50mg「第一三共」, methylthioninium chloride hydrate 50 mg/10 mL; approval number 22600AMX01391; marketing start March 2015; revised October 2024 (4th edition, re-examination result). Indication (efficacy field): 中毒性メトヘモグロビン血症 (toxic methemoglobinemia). Dosage: 1-2 mg/kg IV over at least 5 minutes for infants over 3 months, children and adults, repeatable after 1 hour, maximum cumulative 7 mg/kg; neonates and infants up to 3 months 0.3-0.5 mg/kg. Contraindicated in G6PD deficiency and NADPH reductase deficiency. Japanese-language quote (record field, efficacy line); non-Latin quote, hand-check. NOTE ON HOST: PMDA's own ResultDataSetPDF endpoint returned a different product's label (cefmetazole) on every attempt, so this JAPIC PINS copy of the same 添付文書 is cited instead. Study type: regulatory record.